Disposable Immunosensor for Synthetic Cannabinoid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current analytical methods for detecting synthetic cannabinoids like UR-144 and XLR-11 are inadequate as they require expensive equipment and trained staff, and existing immunoassays lack cross-reactivity with these compounds and their metabolites, hindering forensic and clinical analysis.
Innovation Solution
Development of antibodies specifically designed to detect UR-144, XLR-11, and their metabolites, which can be incorporated into assays and kits, providing high sensitivity and specificity without cross-reactivity with other synthetic cannabinoids, enabling effective detection and quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mass-spectrometry based methods (GC-MS, LC-MS) are used for detection, then measurement precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent employs disposable immunosensor strips with pre-immobilized antibodies instead of expensive, complex mass-spectrometry equipment. These single-use sensors provide sufficient detection accuracy for synthetic cannabinoids while eliminating the need for costly instrumentation and reducing device complexity.
Solution Approach 2:
The patent replaces the complex mechanical and computational systems of mass-spectrometry with a simpler biochemical detection system using antibody-antigen binding. The immunosensor utilizes specific antibody binding to detect synthetic cannabinoids, substituting sophisticated instrumental analysis with a more straightforward biological recognition system.
2Measurement precision
If mass-spectrometry based methods are used for detection, then measurement precision is improved, but ease of operation deteriorates
Solution Approach 1:
The disposable immunosensor strips are designed for simple plug-and-play operation without requiring highly trained personnel. Users can perform detection by simply adding sample to the strip, eliminating the complex sample preparation, instrument operation, and data analysis required by mass-spectrometry systems.
Solution Approach 2:
The immunosensor performs self-detection through built-in antibody binding and signal generation mechanisms. The system automatically processes the sample and generates results without requiring expert interpretation, making operation accessible to personnel without specialized training in mass-spectrometry.
3Ease of manufacture
If existing immunoassay antibodies are used, then ease of manufacture is improved, but measurement precision deteriorates
Solution Approach 1:
The patent develops antibodies with specific local structural recognition capabilities tailored to detect synthetic cannabinoids and their metabolites. The antibodies are engineered to recognize specific molecular features of UR-144, XLR-11, and related compounds, providing precise detection while maintaining ease of immunosensor manufacturing.
Solution Approach 2:
The patent optimizes antibody parameters including affinity, specificity, and cross-reactivity profiles through selective immunization and screening processes. By adjusting these biochemical parameters, the antibodies achieve high measurement precision for synthetic cannabinoid detection while remaining compatible with standard immunosensor manufacturing procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies enable sensitive and specific detection of UR-144 and XLR-11, including their metabolites, in samples, improving forensic toxicological and clinical analysis capabilities without the need for expensive equipment or highly trained personnel.
Implementation Method 1
antibodies which bind to UR-144, XLR-11 and/or their metabolites
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antobodies based on novel immunogens. These antobodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and metabolites or derivatives thereof.